NO331211B1 - ¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿ - Google Patents

¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿

Info

Publication number
NO331211B1
NO331211B1 NO20075527A NO20075527A NO331211B1 NO 331211 B1 NO331211 B1 NO 331211B1 NO 20075527 A NO20075527 A NO 20075527A NO 20075527 A NO20075527 A NO 20075527A NO 331211 B1 NO331211 B1 NO 331211B1
Authority
NO
Norway
Prior art keywords
treatment
skin
connective tissue
tissue disorders
beta
Prior art date
Application number
NO20075527A
Other languages
English (en)
Norwegian (no)
Other versions
NO20075527L (no
Inventor
Morten Sloth Weidner
Hans Christian Wulff
Original Assignee
Astion Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Pharma As filed Critical Astion Pharma As
Publication of NO20075527L publication Critical patent/NO20075527L/no
Publication of NO331211B1 publication Critical patent/NO331211B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20075527A 2005-04-13 2007-11-02 ¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿ NO331211B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500529 2005-04-13
PCT/DK2006/050013 WO2006108424A2 (en) 2005-04-13 2006-04-12 Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin

Publications (2)

Publication Number Publication Date
NO20075527L NO20075527L (no) 2008-01-14
NO331211B1 true NO331211B1 (no) 2011-10-31

Family

ID=36703472

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075527A NO331211B1 (no) 2005-04-13 2007-11-02 ¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿

Country Status (28)

Country Link
US (4) US8426475B2 (https=)
EP (1) EP1719507B1 (https=)
JP (1) JP5021621B2 (https=)
KR (1) KR101355422B1 (https=)
CN (1) CN101203214B (https=)
AR (1) AR054249A1 (https=)
AT (1) ATE473735T1 (https=)
AU (1) AU2006233502B2 (https=)
BR (1) BRPI0609361A2 (https=)
CA (1) CA2604758C (https=)
CY (1) CY1111541T1 (https=)
DE (1) DE602006015387D1 (https=)
DK (1) DK1719507T3 (https=)
EA (1) EA016082B1 (https=)
ES (1) ES2348920T3 (https=)
HR (1) HRP20100552T1 (https=)
IL (1) IL186491A (https=)
MX (1) MX2007012794A (https=)
MY (1) MY147864A (https=)
NO (1) NO331211B1 (https=)
NZ (1) NZ562940A (https=)
PL (1) PL1719507T3 (https=)
PT (1) PT1719507E (https=)
RS (1) RS51464B (https=)
SI (1) SI1719507T1 (https=)
TW (1) TWI366457B (https=)
WO (1) WO2006108424A2 (https=)
ZA (1) ZA200708748B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0604826D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders and pain
US8268813B2 (en) 2006-07-10 2012-09-18 Intervet International B.V. Zilpaterol enantiomer compositions and methods of making and using such compositions
GB0624757D0 (en) * 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
GB0805535D0 (en) 2008-03-27 2008-04-30 Univ Leicester Scar prevention
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith
CN102267917B (zh) * 2011-06-15 2013-07-31 浙江工业大学 一种盐酸甲氧那明的合成方法
WO2013171330A1 (en) * 2012-05-18 2013-11-21 Intervet International B.V. A method of enhancing performance in broiler chickens
GB2513297A (en) 2013-03-08 2014-10-29 Univ Leicester Methods
CN104606177B (zh) * 2014-11-21 2018-02-02 苏州君宁新药开发中心有限公司 左旋(r)沙丁胺醇制剂在治疗皮肤及粘膜创伤溃疡的药物应用
WO2018000098A1 (en) * 2016-06-30 2018-01-04 Cipher Pharmaceuticals Inc. Treatment of inflammatory myopathies
CN106580978A (zh) * 2016-11-30 2017-04-26 郑州仁宏医药科技有限公司 一种治疗皮炎的西药组合物及其应用
WO2019032147A1 (en) * 2017-08-10 2019-02-14 Avro Life Sciences, Inc. TRANSDERMAL DRUG DELIVERY SYSTEM
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
WO2020198466A1 (en) * 2019-03-27 2020-10-01 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
EP4076422A4 (en) 2019-12-18 2024-01-24 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
CN112300237A (zh) * 2020-04-13 2021-02-02 苏州恩泰新材料科技有限公司 海豹胆酸的制备方法及其应用
WO2022074228A1 (en) * 2020-10-09 2022-04-14 Mc2 Therapeutics Ltd Treatment of dermatological conditions
CN116236467B (zh) * 2023-02-07 2023-10-27 中国人民解放军总医院 西马特罗或其衍生物的新用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097073A1 (en) * 2002-04-19 2003-11-27 Astion Development A/S Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
WO2004073614A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA7464B (en) 1973-01-16 1974-11-27 J Voorhees Treatment of proliferating skin diseases with papavine alkaloids
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
SU895445A1 (ru) * 1980-05-15 1982-01-07 Военно-Медицинская Краснознаменная Академия Им. С.М.Кирова Способ лечени кожных форм красной волчанки
US4574129A (en) 1984-01-31 1986-03-04 Bristol-Myers Company Topical nonsteroidal anti-inflammatory methods
JPS61154201A (ja) 1984-12-26 1986-07-12 Matsushita Electric Ind Co Ltd 誘電体フイルタ
US4699777A (en) 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea
PH25150A (en) 1986-06-05 1991-03-13 Ciba Geigy Ag Novel pharmaceutical preparation for topical application
US4980159A (en) 1989-05-23 1990-12-25 Bristol-Myers Squibb Company Processes and compositions for the topical application of β-adrenergic agonists for pilomotor effects
RU2092105C1 (ru) * 1989-11-20 1997-10-10 Нижегородский научно-исследовательский кожно-венерологический институт Способ определения терапевтической тактики у больных очаговой склеродермией и дискоидной красной волчанкой
DE4014252A1 (de) 1990-05-04 1991-11-07 Boehringer Ingelheim Vetmed Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
ES2053333T3 (es) 1990-07-26 1994-07-16 Searle & Co Sistema polimerico para la administracion de farmacos.
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
GB9107196D0 (en) * 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
JP3294876B2 (ja) 1992-07-20 2002-06-24 トキコ株式会社 給油装置
AU1533495A (en) 1994-01-12 1995-08-01 Byk Nederland Bv Phenyl ethanol amine ethers and uses thereof as beta-adreno-receptor agonists
JPH07304647A (ja) 1994-05-09 1995-11-21 Kao Corp マッサージ用組成物
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
GB9510162D0 (en) * 1995-05-19 1995-07-12 Bouras Elias Compositions for the treatment of skin conditions
JPH09110674A (ja) 1995-10-16 1997-04-28 Kao Corp 浴用剤組成物
FR2740040B1 (fr) 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
CA2286913C (en) 1997-04-30 2008-12-09 Bridge Pharma, Inc. Composition and methods using an eutomer
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002040021A2 (en) 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
JP4657605B2 (ja) 2001-12-03 2011-03-23 ワイス・エルエルシー 細胞質内ホスホリパーゼａ２の阻害剤
WO2003088997A2 (en) 2002-04-22 2003-10-30 Universiteit Utrecht Holding B.V. Reduction of unwanted immune reactions
US20060100181A1 (en) * 2002-05-03 2006-05-11 Jost-Price Edward R Combinations for the treatment of inflammatory skin disorders
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
BR0314713A (pt) * 2002-09-24 2005-07-26 Combinatorx Inc Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
US20040229849A1 (en) 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
ZA200505523B (en) 2002-12-20 2006-09-27 Amgen Inc Asthma and allergic inflammation modulators
EP1613266A4 (en) * 2003-04-15 2009-05-06 Theraquest Biosciences Llc METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF
JP2009514779A (ja) 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
SG148198A1 (en) * 2003-11-21 2008-12-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
EP1725226A2 (en) * 2004-03-17 2006-11-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
WO2005102296A2 (en) 2004-04-23 2005-11-03 Heptagen Limited Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
WO2006027579A2 (en) 2004-09-07 2006-03-16 Sosei R & D Ltd. The treatment of inflammatory disorders and pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097073A1 (en) * 2002-04-19 2003-11-27 Astion Development A/S Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004073614A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
TW200719882A (en) 2007-06-01
ES2348920T3 (es) 2010-12-17
SI1719507T1 (sl) 2010-11-30
AU2006233502A1 (en) 2006-10-19
HRP20100552T1 (hr) 2010-11-30
MX2007012794A (es) 2008-02-22
PL1719507T3 (pl) 2010-12-31
EA016082B1 (ru) 2012-02-28
IL186491A (en) 2011-12-29
IL186491A0 (en) 2008-08-07
CN101203214B (zh) 2012-11-21
CA2604758C (en) 2014-11-25
BRPI0609361A2 (pt) 2010-03-30
US20190125699A1 (en) 2019-05-02
JP5021621B2 (ja) 2012-09-12
WO2006108424A2 (en) 2006-10-19
CN101203214A (zh) 2008-06-18
WO2006108424A3 (en) 2006-12-14
WO2006108424A9 (en) 2007-08-09
DE602006015387D1 (de) 2010-08-26
US20130237607A1 (en) 2013-09-12
PT1719507E (pt) 2010-10-21
EA200702204A1 (ru) 2008-04-28
JP2008535873A (ja) 2008-09-04
AU2006233502B2 (en) 2011-07-28
CY1111541T1 (el) 2015-08-05
US9907765B2 (en) 2018-03-06
TWI366457B (en) 2012-06-21
RS51464B (sr) 2011-04-30
DK1719507T3 (da) 2010-11-01
KR101355422B1 (ko) 2014-02-06
KR20080005957A (ko) 2008-01-15
ATE473735T1 (de) 2010-07-15
EP1719507B1 (en) 2010-07-14
US20170157068A1 (en) 2017-06-08
NO20075527L (no) 2008-01-14
NZ562940A (en) 2010-02-26
AR054249A1 (es) 2007-06-13
EP1719507A1 (en) 2006-11-08
ZA200708748B (en) 2010-03-31
HK1091739A1 (en) 2007-01-26
US8426475B2 (en) 2013-04-23
US20060235048A1 (en) 2006-10-19
MY147864A (en) 2013-01-31
CA2604758A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
NO331211B1 (no) ¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
NZ603985A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
BRPI0918868B8 (pt) compostos moduladores do receptor de nmda e composições compreendendo os mesmos
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
MX2009009623A (es) Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide.
BR112014009851A2 (pt) moduladores de receptor de nmda e usos dos mesmos
EA200801243A1 (ru) Фармацевтическое применение замещенных амидов
UY30442A1 (es) Composiciones farmaccuticas de ropinirol, mctodos de uso, proceso de preparacinn y aplicaciones.
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
EP2452686A3 (en) Methods and compositions for prevention and treatment of diabetic and aged skin
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
NO20064584L (no) Tetrahydropyridoindolderivater
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
TW200611695A (en) Pyrrolopyridine derivatives
BRPI0615690B8 (pt) compostos heterocíclicos de hidroxamato, seus usos e composição farmacêutica
NO20090205L (no) Cykliske derivater som modulatorer av kjemokin reseptor aktiviteten
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO2020068950A8 (en) Hdac1,2 inhibitors

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CIPHER PHARMACEUTICALS INC, CA

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTION PHARMA A/S, DK

CREP Change of representative

Representative=s name: VALUA APS, BORGMESTER JENSENS ALLE 25C, 1. SAL, 2100

MM1K Lapsed by not paying the annual fees